



CENTRAL PHARMACEUTICAL JSC No.25

Số: 159/CBTT- TW25

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Ho Chi Minh City, June 24, 2026

**INFORMATION DISCLOSURE
ON THE ELECTRONIC PORTAL OF THE STATE SECURITIES COMMISSION AND
THE HANOI STOCK EXCHANGE**

Dear - State Securities Commission
- Hanoi Stock Exchange

1. Company Name: TW25 PHARMACEUTICAL JOINT STOCK COMPANY
2. Stock Code: UPH
3. Head Office Address: 448B Nguyen Tat Thanh Street, Ward 18, District 4, Ho Chi Minh City
4. Telephone: 0283.9414.967 Fax: 0283.9414.975
5. Person responsible for information disclosure: DANG HOAI NAM
6. Position: Authorized person for information disclosure.
7. Type of information disclosed: Periodic Irregular 24h On request
8. Content of the Announcement:

On June 24, 2026, the Board of Directors of Central Pharmaceutical Company No. 25 issued Resolution No. 42/NQ-HĐQT – TW25 approving the selection of Ernst & Young Vietnam Co., Ltd. as the auditor for the Company's semi-annual and annual financial statements for 2026.

This information was published on the Company's website on June 24, 2026, at www.uphace.vn.

We commit that the information published above is true and accurate and we are fully responsible before the law for the information published.

Best regards./.

Attached: Resolution No. 42/NQ-HĐQT – TW25 dated June 24, 2026.

Authorized person for information disclosure



Mr. Dang Hoai Nam

RESOLUTION**BOARD OF DIRECTORS OF CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY 25****Regarding: Selection of Auditing Firm for the 2026 Financial Statements**

- Law on Enterprises No. 59/2020/QH14, passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Law on Securities No. 54/2019/QH14, passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019;
- Based on the Charter of Central Pharmaceutical Company No. 25; Based on the Internal Regulations on Corporate Governance of Central Pharmaceutical Company No. 25;
- Based on the results of the written consultation with the members of the Board of Directors on June 23, 2026,

RESOLUTION


Article 1: It is decided to select Ernst & Young Vietnam Co., Ltd. as the auditor for the semi-annual and annual financial statements for 2026 of Central Pharmaceutical Company No. 25.

Article 2: The General Director of the Company is authorized to sign the audit contract and direct relevant departments to implement Article 1 of this Resolution effectively, in accordance with Company regulations and current laws.

Article 3: The members of the Board of Directors and the General Director's Office are responsible for implementing this Resolution. This Resolution takes effect from the date of signing./.

Recipient:

- As per Article 3;
- For the Board of Directors' records.

On behalf of the Board
Chairman *[Signature]*

Dr. **Pham Thi Xuan Huong**